Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history.
Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong demand for its cancer diagnostics business and medical devices easing procedure-volume concerns. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis.
So which healthcare giant offers the more compelling investment case for investors? Let’s dive into it.
An operating room with a doctor monitoring a patient’s vital signs during surgery with a medical device.
Both healthcare giants beat quarterly estimates and raised their outlooks, suggesting continued resilience across their businesses. The key question for investors is whether Johnson & Johnson’s (NYSE:JNJ) pharmaceutical growth story or Abbott Laboratories’ (NYSE:ABT) expanding diagnostics and medical devices businesses offer the more compelling investment case going forward.
Bull Case
Johnson & Johnson’s (NYSE:JNJ) pharmaceutical unit was an optimistic factor, as it helped increase total sales, generating $16.38 billion in quarterly sales and exceeding analysts’ estimate of $16.1 billion. The healthcare giant now expects its annual sales to be around $101.1 billion at the midpoint, compared with $100.8 billion previously. In another optimistic feat, it raised its adjusted earnings per share forecast to $11.68 at the midpoint, from a previous $11.55 per share.
Revenue from Johnson & Johnson’s (NYSE:JNJ) Stelara, which treats psoriasis, Crohn’s disease, and other autoimmune conditions, dropped over 55% in the quarter to $740 million due to patent loss. However, the company’s cancer and newer immunology drugs can be seen countering this loss, as sales of Tremfya, its psoriasis and inflammatory bowel disease drug, rose 72.5% to $2 billion, considerably exceeding the estimate of $1.74 billion.
The most encouraging sign for investors thus may be Johnson & Johnson’s (NYSE:JNJ) ability to absorb a significant patent-related decline in Stelara sales while still raising its full-year outlook. Strong performance from newer drugs such as Tremfya suggests the company’s pipeline is successfully offsetting losses from older products.
On the other hand, Abbott Laboratories (NYSE:ABT) reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items, and reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, suggesting confidence in its operations. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58.
Abbott Laboratories (NYSE:ABT) diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion, emerging as one of the company’s strongest performers during the quarter. This was driven by strong adoption in electrophysiology, diabetes care (such as CGM systems), and expanding cancer screening diagnostics. William Blair stated that the company’s cancer diagnostics results should improve sentiment around the Exact Sciences acquisition, with growth in medical devices helping offset concerns surrounding hospital procedure volumes.
Bear Case
Johnson & Johnson’s (NYSE:JNJ) MedTech segment was comparatively less impressive during the quarter, with sales slightly missing expectations. Management attributed some of the weakness to temporary headwinds, including inventory-related pressures in China that weighed on Electrophysiology sales and softer U.S. procedure trends affecting Abiomed. While Johnson & Johnson (NYSE:JNJ) expects these challenges to improve over time, investors may want to watch whether its MedTech business returns to its historical growth trajectory in the coming quarters. Sustained weakness in these businesses could limit the company’s ability to diversify its growth beyond pharmaceuticals.
On the other hand, while Abbott Laboratories’ (NYSE:ABT) outlook remains encouraging, a meaningful portion of its expected growth acceleration in the second half of 2026 depends on the successful commercialization of several pipeline products. Management has expressed confidence that sales and earnings growth will accelerate in the second half of 2026. While this outlook is supported by improving momentum across multiple business segments, investors will need to see that acceleration materialize over the coming quarters. Notably, Abbott Laboratories (NYSE:ABT) reaffirmed rather than raised its full-year comparable sales growth guidance of 6.5% to 7.5%, suggesting that management remains prudent despite its strong second-quarter performance.
What Does Hedge Fund Ownership Say?
Hedge fund ownership for the two stocks provides additional insight into the investment thesis. According to Insider Monkey data, Johnson & Johnson (NYSE:JNJ) seems to be growing in popularity among hedge funds, with its ownership going from 104 in fiscal Q4 2025 to 113 in fiscal Q1 2026. Some notable stakes for Johnson & Johnson (NYSE:JNJ) come from Fisher Asset Management, GQG Partners, and AQR Capital Management, with Balyasny Asset Management‘s position jumping by 1,411% to $146 million.
Hedge fund sentiment for Abbott Laboratories (NYSE:ABT) also improved moderately from last quarter, going from 71 in fiscal Q4 2025 to 73 in fiscal Q1 2026. While the increase is modest, it suggests that institutional investors continue to maintain confidence in Abbott Laboratories’ (NYSE:ABT) long-term growth prospects following its strong quarterly performance.
Johnson & Johnson’s (NYSE:JNJ) earnings highlight the strength of its pharmaceutical pipeline and its ability to navigate patent losses, while Abbott Laboratories’ (NYSE:ABT) results shed light on the growing importance of its diagnostics and medical device businesses. Both companies delivered strong quarterly results, suggesting that investors may be choosing between two different growth opportunities rather than one clear winner.
While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Hedge Fund Resource Center